Live Chat

交易 BioNTech BNTX

BioNTech實時圖表

金融工具基礎知識

Weekly Search
Weekly
Daily
日期  關閉 更改 更改(%): 開倉

最新新聞

Christine Voong 2024 Nov 21, 10:18

華為晶片Ascend 910C計劃2025年量產,面臨美國禁令與台積電供應挑戰

Christine Voong 2024 Nov 21, 08:05

黃金價格走勢:俄烏衝突推動黃金價格上漲,美元與利率預期施壓金價

Christine Voong 2024 Nov 21, 04:13

美元匯率回升,美元指數攀升至一年高點,市場焦點轉向川普政策與聯準會

So Ze Dong 2024 Nov 20, 16:00

11月21日財經:輝達財報亮眼卻股價下跌,美股指數表現平平

Christine Voong 2024 Nov 20, 10:20

歐洲股市開盤上漲,原油價格小幅上漲,市場聚焦經濟數據與俄烏局勢

Christine Voong 2024 Nov 20, 08:27

比特幣價格走勢:創新高後持穩於92,000美元,市場聚焦川普政策

Christine Voong 2024 Nov 20, 04:50

美股指數波動:Nvidia推動標普500指數與納斯達克指數上漲,市場情緒回升

So Ze Dong 2024 Nov 20, 01:00

11月20日財經:輝達主導科技股領漲,俄烏局勢升溫避險情緒短暫回升

聯絡方式

點差

1.0525

點差(%)

1.0364 %

槓桿

1:10

隔夜利息(買入)

-0.0597 %

隔夜利息(賣出)

-0.0292 %

貨幣

USD

交易時間

市場關閉

星期四

14:31 - 20:59

星期一

14:31-20:59

星期二

14:31-20:59

星期三

14:31-20:59

星期五

14:31-20:59

分析與統計

開倉

---

上一次平倉

---

52 週高點/低點

--- – ---

市值

25508335616

流通股份

239740000

收益日期(下一個)

0000-00-00

現金殖利率 

2022-06-17

除息日

2022-06-02

遠期年股息率

0

遠期年現金殖利率

0

每股盈餘

-2.05

了解有關此金融工具的詳細資訊

BioNTech BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac

相關工具

資產
出售
購買
更改(%):
查看所有金融工具
Trustpilot
Live Chat